Trial Profile
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as Pre Transplant INDUCTION and Post Transplant Consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as Pre Transplant INDUCTION and Post Transplant Consolidation or Continuous Treatment With CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 Cycles) Without Transplant, All Followed by MAINTENANCE With LENALIDOMIDE (R) Versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Cyclophosphamide; Dexamethasone; Dexamethasone; Granulocyte colony-stimulating factors; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms FORTE
- 04 Dec 2023 Results assessing predictors of unsustained MRD-negativity in patients enrolled in the FORTE trial, published in the Blood.
- 29 Nov 2023 Planned End Date changed from 1 Oct 2025 to 1 Oct 2033.
- 14 Dec 2022 Results of subgroup analysis (n=396) describing the outcomes of enrolled patients according to their cytogenetic risk, published in the Lancet Oncology